Clinical Trials in Manchester - 30 Recruiting Industry Studies

Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca · started 2020-08-18

📍 London · Manchester · Sutton

NCT04482309 on ClinicalTrials.gov ↗

Recruiting Phase 1/Phase 2

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

Renal Cell Carcinoma
Merck Sharp & Dohme LLC · started 2025-07-20

📍 Edinburgh · Glasgow · London · Cardiff · Manchester

NCT07049926 on ClinicalTrials.gov ↗

Recruiting Phase 2

EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety

Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive
Eloxx Pharmaceuticals, Inc. · started 2026-06-30

📍 Liverpool · London · Manchester

NCT07523581 on ClinicalTrials.gov ↗

Recruiting Phase 3

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

Von Willebrand Disease, Type 3
Hoffmann-La Roche · started 2025-06-27

📍 London · Manchester

NCT06998524 on ClinicalTrials.gov ↗

Recruiting Phase 3

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Colon Adenocarcinoma, Rectal Adenocarcinoma
Merck Sharp & Dohme LLC · started 2025-07-16

📍 Birmingham · London · Oxford · Coventry · Manchester

NCT06997497 on ClinicalTrials.gov ↗

Recruiting Phase 3

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Von Hippel-Lindau Disease, Malignant Neoplasms
Merck Sharp & Dohme LLC · started 2026-03-23

📍 Glasgow · London · Manchester

NCT07405164 on ClinicalTrials.gov ↗

Active Phase 3

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Cancer
Hoffmann-La Roche · started 2017-09-20

📍 London · Manchester · Metropolitan Borough of Wirral · Nottingham · Surrey

NCT03148418 on ClinicalTrials.gov ↗

Active

An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

Von Willebrand Disease, Type 3
Hoffmann-La Roche · started 2025-04-29

📍 London · Manchester

NCT06883240 on ClinicalTrials.gov ↗

Active Phase 3

Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

Congenital Hyperinsulinism
Zealand Pharma · started 2019-05-02

📍 Glasgow · Liverpool · London · Manchester

NCT03941236 on ClinicalTrials.gov ↗

Recruiting Phase 2/Phase 3

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

HER2-positive Breast Cancer
Hoffmann-La Roche · started 2026-05-21

📍 Leicester · London · Manchester · Sutton

NCT07413939 on ClinicalTrials.gov ↗

Recruiting Phase 2/Phase 3

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura
argenx · started 2025-10-20

📍 Cardiff · Glasgow · Manchester

NCT07194850 on ClinicalTrials.gov ↗

Recruiting Phase 2/Phase 3

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics · started 2025-01-28

📍 Aberdeen · Birmingham · Cambridge · Glasgow · Leeds

NCT06788990 on ClinicalTrials.gov ↗

Recruiting Phase 3

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
AstraZeneca · started 2026-05-05

📍 Edinburgh · Hampshire · Leeds · London · Manchester

NCT07509151 on ClinicalTrials.gov ↗

Recruiting Phase 3

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Non-small Cell Lung Cancer
Boehringer Ingelheim · started 2026-01-16

📍 Cardiff · Edinburgh · London · Manchester · Sutton

NCT07195695 on ClinicalTrials.gov ↗

Active Phase 3

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Gastric Cancer, Gastroesophageal Junction Cancer
AstraZeneca · started 2024-03-04

📍 Cambridge · London · Manchester · Oxford · Taunton

NCT06346392 on ClinicalTrials.gov ↗

Recruiting Phase 3

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Pfizer · started 2025-09-28

📍 Blackburn · Cardiff · Plymouth · Torquay · London

NCT07028853 on ClinicalTrials.gov ↗

Recruiting Phase 2/Phase 3

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Mirati Therapeutics Inc. · started 2020-12-02

📍 Birmingham · Edinburgh · Kent · Leicester · London

NCT04613596 on ClinicalTrials.gov ↗

Recruiting Phase 2

Rescue of Nephrons With ALE.F02 (RENAL-F02)

Glomerulonephritis Rapidly Progressive
Alentis Therapeutics AG · started 2023-09-07

📍 Birmingham · Cambridge · Liverpool · London · Manchester

NCT06047171 on ClinicalTrials.gov ↗

Recruiting Phase 2

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
Boehringer Ingelheim · started 2023-10-13

📍 Leicester · London · Manchester · Newcastle upon Tyne

NCT05882058 on ClinicalTrials.gov ↗

Recruiting Phase 1/Phase 2

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Boehringer Ingelheim · started 2024-06-03

📍 Cardiff · Leeds · London · Manchester · Newcastle upon Tyne

NCT06324357 on ClinicalTrials.gov ↗

Recruiting Phase 3

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

Healthy
Pfizer · started 2025-08-25

📍 Bristol · London · Manchester · Truro · Southampton

NCT07160244 on ClinicalTrials.gov ↗

Recruiting Phase 2/Phase 3

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer
AbbVie · started 2025-12-10

📍 London · Manchester

NCT07155187 on ClinicalTrials.gov ↗

Recruiting Phase 2/Phase 3

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy
Cabaletta Bio · started 2023-12-20

📍 London · Manchester · Salford

NCT06154252 on ClinicalTrials.gov ↗

Recruiting Phase 3

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid Tumors, Hematologic Malignancies
Merck Sharp & Dohme LLC · started 2018-08-21

📍 Aberdeen · Cambridge · Edinburgh · Manchester · Sheffield

NCT03486873 on ClinicalTrials.gov ↗

No trials match your search.

Browse by city

London · 118 Manchester · 30 Glasgow · 27 Cambridge · 27 Birmingham · 24 Leicester · 23 Bristol · 23 Leeds · 22 Sutton · 19 Oxford · 19 Liverpool · 18 Edinburgh · 15 Nottingham · 14 Cardiff · 14 Newcastle upon Tyne · 13 Sheffield · 12

Browse by condition

Obesity · 5 Chronic Lymphocytic Leukemia · 5 Cancer · 4 Breast Neoplasms · 3 Non-small Cell Lung Cancer · 3 Small Lymphocytic Lymphoma · 3 Multiple Myeloma · 3 Hypertension · 3 Heart Failure · 3 Triple Negative Breast Neoplasms · 2 Lymphoma, Non-Hodgkin · 2 Lymphoma, Follicular · 2 Lymphoma, Large B-Cell, Diffuse · 2 Gastric Cancer · 2 Metastatic Prostate Cancer · 2 Overweight · 2

Cite this page

Priya Life Science (2026). Clinical Trials in the UK Tracker. Available at: https://priyalifescience.com/clinical-trials-uk/city/manchester (Accessed: 11 July 2026).

Source: ClinicalTrials.gov, U.S. National Library of Medicine — industry-sponsored studies in a recruiting status with at least one UK site, most recently updated first, refreshed daily. This is a curated slice of the registry, not every UK trial; UK studies may also be registered on ISRCTN. Listing here is informational and not medical advice; eligibility is determined by each study team. Patients should discuss participation with their clinician. Compare pay for the teams running these studies in our UK Pharma Salary Guide, or see our Ireland, EU and USA trackers.